Navigation Links
Sentrx Growth Continues with Four New Clients in Second Quarter
Date:7/31/2008

Sentrx, a leading provider of drug safety services, gained four new contracts in the second quarter, including a risk evaluation and mitigation strategy (REMS). The company was also awarded a significant contract expansion.

Little Falls, NJ (PRWEB) July 31, 2008 -- Sentrx, a leading provider of http://www.sentrx.com/drug_safety_services.shtml [drug safety __title__ drug safety] services, announced today that the company signed four new multi-year contracts in the second quarter of 2008. Combined with wins from the first quarter, Sentrx gained nine clients in the first six months of 2008.

Sentrx pioneered the concept of http://www.sentrx.com/drug_safety_services.shtml [drug safety __title__ drug safety] outsourcing for clinical trial safety monitoring, post-marketing safety surveillance, and risk management programs. The multi-year contracts initiated in the second quarter of 2008 include:

  • A risk evaluation and mitigation strategy (REMS) for a biopharmaceutical company
  • Post-marketing safety surveillance with managed safety system hosting for a specialty pharmaceutical company
  • Clinical trial safety monitoring with managed safety system hosting for two biopharmaceutical companies
In addition to the new contracts, Sentrx was awarded a significant contract expansion from an existing large biopharmaceutical client. Sentrx will perform adverse event case processing for additional post-marketed products, doubling the volume of work in 2008.

Sentrx went live with one of the first FDA-required REMS implementations in July, meeting the client's extremely tight timeframe for successful product launch. The Sentrx SafetyTrak® Technology Suite was configured to create a controlled distribution program, ensuring that only registered hospitals order and receive the new drug. Health care professionals in the Sentrx Safety Response Center register hospitals that wish to utilize the treatment in certain post-surgical patients.

"Our second quarter results contain more than one milestone. Besides supporting one of the first REMS, Sentrx will be implementing its first Empirica(tm) Trace instance for a client, making us the only drug safety services provider to offer a choice of http://www.sentrx.com/consulting.shtml [pharmacovigilance __title__ pharmacovigilance] systems," said Joseph Albano, Chief Executive Officer of Sentrx. "Our unique blend of information technology talent, operational excellence and good clinical practices continues to meet the needs of the biopharmaceutical market."

About Sentrx:
Sentrx is a leading provider of technology-enabled solutions and services for global drug safety. Its mission is to help pharmaceutical, biotechnology, medical device, and consumer health companies document the safety profile of their products during clinical development and post-approval, enabling them to minimize risks and maximize benefits. Through its multilingual Safety Response Center, Sentrx delivers a unique combination of highly skilled people, exclusive technology, and best practices in drug safety monitoring. To learn more about Sentrx, please call 1-888-399-8032, extension 261, or click here for a short movie: (www.sentrx.com/impactmovie).
        
Media Contact:
Jill Notte
Executive Director, Marketing
150 Clove Road
Little Falls, NJ 07424
1-973-812-7575 ext. 261
http://www.sentrx.com

Read the full story at http://www.prweb.com/releases/2008/07/prweb1164594.htm


'/>"/>
Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Explosive Growth in Medical Tourism and Rise of Retail Clinics Provide Huge Cost Savings for Patients
2. FGX International Reports Strong Sales and Earnings Growth for the Second Quarter and First Six Months of 2008
3. Hanger Orthopedic Group, Inc. Beats First Call Q2 EPS Estimates by $0.05 on 13% Sales Growth and 57.2% Growth in Net Income
4. VNUS Medical Technologies Reports Second-Quarter 2008 Results: 25% Growth in Net Product Revenues and 38% Growth in Unit Sales
5. Ingenious Med Continues Record Customer Growth and Approaches Key Milestones
6. Southern Home Medicals Encore Medical Staffing Division Poised to Benefit from Major Growth in Nursing Industry
7. Medco Reports Record Second-Quarter 2008 GAAP Diluted EPS; Reflects Growth of 34.2 Percent; Raises and Narrows 2008 Guidance
8. Perrigo Company to Present at The Oppenheimer & Co. Inc. 8th Annual Consumer Growth Conference
9. Thermage, Inc. to Present at the Fourth Annual Collins Stewart Growth Conference
10. Cyberonics to Present at Collins Stewart Fourth Annual Growth Conference
11. Sunesis Pharmaceuticals to Present at the Collins Stewart Fourth Annual Growth Conference
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Sentrx Growth Continues with Four New Clients in Second Quarter
(Date:7/24/2017)... ... , ... “Journey to the Light: The Quest for Happiness and Love. . ... to finding herself. “Journey to the Light: The Quest for Happiness and Love. ... writer of newsletters, manuals, and articles, who has recently decided to expand her literary ...
(Date:7/23/2017)... (PRWEB) , ... July 23, 2017 , ... A ... in St. Louis, and led by the Minneapolis Veterans Administration Health Care System overwhelmingly ... of the disease offers very few benefits. , In the cases involved with ...
(Date:7/23/2017)... ... 23, 2017 , ... Technology is making it easier for ... tools are helping patients become more actively involved in their care and maintaining ... survey, released today by the American Hospital Association’s (AHA) Health Forum. , According ...
(Date:7/23/2017)... ... July 23, 2017 , ... Viora Ltd., a ... US Patent No. 9,038,640 by the United States Patent and Trademark Office. The ... combination of Switching, Vacuum, and Cooling mechanisms to further increase the efficacy and ...
(Date:7/21/2017)... ... July 21, 2017 , ... "As a doctor of lung medicine ... catheters available on the market," said an inventor from Center Valley, Pa. "My idea ... the patient." , He developed the patent-pending PLEURAL SAFE-t-STAT CATHETER KIT to offer an ...
Breaking Medicine News(10 mins):
(Date:7/11/2017)... 11, 2017  The global market for liquid biopsy ... $394.1 million in 2016.  Although in early stages, the ... in particular as a result of the gradual shift ... recent introduction of a significant number of new liquid ... of tumor biomarkers to guide treatment decisions. ...
(Date:7/10/2017)... , July 10, 2017 The Institute for ... methods, is the recipient of a VITROCELL® inhalation exposure ... International Science Consortium. The device, which is designed to ... expose human lung cells to airborne test materials in ... use the VITROCELL® system for testing combustible tobacco products, ...
(Date:7/5/2017)... 5, 2017 Wolfmet 3D  printed tungsten collimator manufactured by ... and manufacturing combine to progress molecular radiotherapy imaging. ... are unable to accurately quantify the radiation absorbed by those ... the success of this radiotherapy treatment has been available — ... ...
Breaking Medicine Technology: